Brokerages Set Merit Medical Systems, Inc. (NASDAQ:MMSI) PT at $92.80

Merit Medical Systems, Inc. (NASDAQ:MMSI) has been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $92.80.

MMSI has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 5th. Canaccord Genuity Group cut their price objective on shares of Merit Medical Systems from $90.00 to $85.00 and set a “buy” rating for the company in a report on Friday, May 1st. Robert W. Baird set a $83.00 price objective on shares of Merit Medical Systems in a report on Friday, May 1st. Barrington Research cut their price objective on shares of Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating for the company in a report on Monday, April 20th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Merit Medical Systems in a report on Monday, April 20th.

Insider Buying and Selling

In related news, insider Brian G. Lloyd acquired 2,000 shares of the business’s stock in a transaction on Thursday, May 7th. The stock was acquired at an average cost of $62.62 per share, with a total value of $125,240.00. Following the acquisition, the insider directly owned 2,000 shares in the company, valued at $125,240. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Lynne N. Ward sold 5,000 shares of the stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $62.61, for a total transaction of $313,050.00. Following the sale, the director directly owned 7,809 shares of the company’s stock, valued at approximately $488,921.49. This trade represents a 39.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.70% of the company’s stock.

Institutional Trading of Merit Medical Systems

A number of institutional investors have recently bought and sold shares of the stock. Tudor Investment Corp ET AL bought a new stake in shares of Merit Medical Systems during the third quarter worth $2,913,050,000. State Street Corp lifted its position in shares of Merit Medical Systems by 1.5% during the fourth quarter. State Street Corp now owns 2,231,048 shares of the medical instruments supplier’s stock worth $196,645,000 after purchasing an additional 32,459 shares during the last quarter. Conestoga Capital Advisors LLC lifted its position in shares of Merit Medical Systems by 3.9% during the first quarter. Conestoga Capital Advisors LLC now owns 2,167,513 shares of the medical instruments supplier’s stock worth $149,407,000 after purchasing an additional 81,030 shares during the last quarter. Fuller & Thaler Asset Management Inc. lifted its position in shares of Merit Medical Systems by 12.7% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock worth $183,137,000 after purchasing an additional 234,682 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of Merit Medical Systems by 7.0% during the fourth quarter. Wellington Management Group LLP now owns 1,327,013 shares of the medical instruments supplier’s stock worth $116,963,000 after purchasing an additional 86,504 shares during the last quarter. 99.66% of the stock is currently owned by institutional investors.

Merit Medical Systems Trading Up 2.4%

Merit Medical Systems stock opened at $70.83 on Friday. The firm has a 50 day moving average of $65.36 and a 200 day moving average of $74.19. The firm has a market capitalization of $4.23 billion, a price-to-earnings ratio of 30.66, a P/E/G ratio of 2.15 and a beta of 0.54. Merit Medical Systems has a 12-month low of $59.74 and a 12-month high of $96.74. The company has a current ratio of 5.08, a quick ratio of 3.46 and a debt-to-equity ratio of 0.45.

Merit Medical Systems (NASDAQ:MMSI) last released its earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.10. The company had revenue of $381.88 million during the quarter, compared to analyst estimates of $377.59 million. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.86 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, research analysts predict that Merit Medical Systems will post 3.62 earnings per share for the current year.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.